FDA grants fast-track status to combination mRNA flu and COVID-19 vaccine candidates

The FDA has granted fast track designation to two combination vaccine candidates that aim to protect adults 50 and older from both influenza and COVID-19, according to a Dec. 16 AJMC report.

These vaccine candidates combine the flu vaccine with the Novavax COVID-19 vaccine, offering a potential single shot to address both diseases.